Medicinal Cannabis for Sleep Disorders: Where Does the Evidence Actually Stand? | Research

The takeaway

Despite cannabis being one of the most common self-treatments for poor sleep, clinical evidence doesn't yet support it as a reliable treatment for any specific sleep disorder.

Read this if you use cannabis for sleep and want an honest look at what the research does and doesn't support, or if you're a clinician fielding questions about medical cannabis for sleep.

What the researchers found

Cannabis is one of the top reasons people cite for using medicinal cannabis, but when you look at the actual clinical trial evidence for specific sleep disorders, the cupboard is surprisingly bare.

For insomnia — the most common reason people use cannabis for sleep — the authors found only a handful of clinical studies, and most were small, short-term, and used different cannabis preparations. Some showed modest improvements in sleep onset and quality, but the evidence isn't strong enough to recommend cannabis over established treatments like cognitive behavioral therapy for insomnia (CBT-I).

For obstructive sleep apnea, early results with dronabinol (synthetic THC) showed some promise in reducing apnea severity, but the sample sizes were small and the effects modest compared to CPAP therapy. For restless legs syndrome, nightmare disorder (especially in PTSD), and narcolepsy, the evidence is even thinner — mostly case reports and very small studies.

The review also flags important concerns about tolerance: cannabis may help sleep initially, but chronic use can lead to tolerance to the sleep-promoting effects, and withdrawal from chronic use reliably disrupts sleep. This creates a potential cycle where cannabis helps short-term but may worsen sleep long-term.

Despite the weak evidence base, the authors note that emerging research is promising, particularly for cannabinoids in nightmare disorder and sleep apnea, and call for properly designed randomized controlled trials.

Why it matters

Millions of people use cannabis to help them sleep, and the cannabis industry actively markets products as sleep aids. But the actual clinical trial evidence is far behind the marketing claims. This review is valuable because it separates anecdotal reports and self-reported survey data from real clinical evidence, giving both patients and clinicians a clear picture of what's actually been demonstrated in controlled settings.

The numbers in context

The review covered evidence across six specific sleep disorders. For obstructive sleep apnea, dronabinol studies involved fewer than 100 total participants. For insomnia, most studies were under 30 participants. The authors found no large-scale, long-term randomized controlled trials of cannabis for any sleep disorder.

How the study worked

Narrative review of the highest-quality clinical evidence available for medicinal cannabis in treating specific sleep disorders: insomnia, obstructive sleep apnea, restless legs syndrome, REM sleep behavior disorder, nightmare disorder, and narcolepsy. Also reviewed evidence on cannabis effects on sleep architecture.

Who was studied

Narrative review summarizing various studies on medicinal cannabis for sleep disorders.

What this study cannot tell us

As a narrative rather than systematic review, the search strategy may not capture all relevant studies. The rapidly growing research landscape means newer studies may have been published since the search was conducted. The review focuses on sleep disorders as defined clinically, which may not capture the broader population using cannabis for general poor sleep quality.

How to read the evidence

This is a narrative review of clinical evidence. While it summarizes the best available data, most of the underlying studies it reviews are small and short-term, making the overall evidence base preliminary.

When this study was published

Published in 2022. Cannabis sleep research is an active area — newer clinical trials may have reported results since this review.

The bigger picture

This review provides important context for the individual sleep studies in the RethinkTHC database. RTHC-00074 (cannabis and sleep architecture) and RTHC-00012 (sleep and zolpidem crossover) examine specific mechanisms, while this review zooms out to ask: does any of this translate to actual clinical benefit? The answer, so far, is 'maybe, but we can't say for sure.' The tolerance and withdrawal concerns echo findings from RTHC-00037 (Budney's withdrawal timeline).

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Will large-scale RCTs of specific cannabinoid formulations (particularly CBD-dominant products) for insomnia show meaningful benefits over placebo? Can cannabinoids help sleep disorders without the tolerance and withdrawal problems seen with chronic THC use? Is there a role for short-term cannabis use in sleep disorders where the main goal is acute symptom relief?

Read the original research

Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far.

Nature and science of sleep, 14, 957-968

Nature and Science of Sleep is a reputable journal focusing on sleep research.

View on PubMed ↗Publisher’s paper ↗

Citation

Maddison, Kathleen J; Kosky, Christopher; Walsh, Jennifer H. (2022). Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far.. Nature and science of sleep, 14, 957-968. https://doi.org/10.2147/NSS.S340949